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ttp://dx.doi.org/10.1016/j.ajpath.2013.02.046In an attempt to reveal deregulated miRNAs associated with the progression of carcinomas developed in
BALB-neuT transgenic mice, we found increased expression of miR-135b during malignancy. Relevantly,
we observed that miR-135b is up-regulated in basal or normal-like human breast cancers, and it
correlates with patient survival and early metastatization. Therefore, we investigated its biological
functions by modulating its expression (up- or down-regulation) in mammary tumor cells. Although no
effect was observed on proliferation in cell culture and in orthotopically injected mice, miR-135b
was able to control cancer cell stemness in a mammosphere assay, anchorage-independent growth
in vitro, and lung cancer cell dissemination in mice after tail vein injections. Focusing on the miR-135b
molecular mechanism, we observed that miR-135b controls malignancy via its direct targets, midline 1
(MID1) and mitochondrial carrier homolog 2 (MTCH2), as proved by biochemical and functional rescuing/
phenocopying experiments. Consistently, an anti-correlation between miR-135b and MID1 or MTCH2 was
found in human primary tumor samples. In conclusion, our research led us to the identiﬁcation of
miR-135b and its targets, MID1 and MTCH2, as relevant coordinators of mammary gland tumor
progression. (Am J Pathol 2013, 182: 2058e2070; http://dx.doi.org/10.1016/j.ajpath.2013.02.046)Supported by grants from the Associazione Italiana per la Ricerca sul
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(PRIN 2008W3KW2A, PRIN, and FIRB Giovani RBFR08F2FS-002 FO),
the Regione Piemonte (Piattaforma Innovativa Biotecnologie per le Scienze
della Vita, ImmOnc project), and Epigenomics Flagship Project EPIGEN,
MIUR-CNR.
F.C. and E.Q. contributed equally to this work as senior authors.Breast cancer is one of the major health problems of the
Western world.1 Although the survival rate has improved
with progress in screening and adjuvant therapies, one third
of the patients present cancer recurrences 10 years after the
diagnosis.2 More than 90% of mortality from cancer is
attributable to metastases and not to the primary tumor from
which metastases arise.3 Identiﬁcation of the genetic and
epigenetic changes foreshadowing metastasis is, thus, one of
the highest priorities for translational cancer research.
Although several protein-coding genes involved in malig-
nancy have been identiﬁed and characterized,4 noncoding
genes, such as miRNAs that have been shown to regulate
many aspects of the metastatic process, have to be charac-
terized.5 Several clinical studies show a correlation between
miRNA expression and recurrence, development of metas-
tasis, and/or survival.6 miRNAs may also contribute to the
metastatic program by modulating the structure of the tumor
microenvironment, inﬂuencing the ability of cancer cells to
move and survive.7 Moreover, miRNAs are involved in thestigative Pathology.
.maintenance of the cancer stem cell (CSC) phenotype by
connecting stemness and metastasis through regulation of
epithelial-to-mesenchymal transition.8 Global miRNA de-
regulation has been shown in breast cancer,9e12 whereas
speciﬁc miRNAs have been associated with clinicopatho-
logical features of breast tumors, such as estrogen and
progesterone receptor expression,13 tumor grade,10 vascular
invasion, or proliferation index.14 As far as breast cancer is
concerned, among other ﬁndings, reduced expression of
miR-145,15 miR-335,16 and miR-126,17 and overexpression
of miR-10b,18 miR-21,19 and miR-21020 were signiﬁcantly
associated with breast cancer invasion and metastasis.
miR-135b and ErbB2þ Mammary CarcinomaHowever, proﬁling studies have been mainly focused on
miRNAs deregulated in primary breast cancer12,21 or in breast
cancer cell lines.22 By contrast, characterization of a deregu-
lated miRNA expression proﬁle during carcinogenesis
progression would permit assessment of their involvement in
tumor development and the efﬁcacy of miRNA targeting
during tumor progression.
BALB-neuTmice are a realisticmodel ofmammary cancer,
because all females develop invasive and metastatic rat
ErbB2þ mammary carcinomas, with a stepwise progression
similar to that of women.23,24 As in several cases of human
mammary cancer, systemicmetastatization is an early event in
BALB-neuT carcinogenesis.25Moreover, the gene expression
pattern associated with cancer progression reveals major
similaritieswith humanErbB2þ breast carcinomas.26,27 In this
study, we show that miR-135a and miR-135b are strongly up-
regulated in invasive carcinomas of BALB-neuT mice
compared with normal mammary tissue. Down-modulation of
miR-135b in cancer cells from BALB-neuT mice revealed its
major role in anchorage-independent growth and lung
metastasis formation. MID1 andMTCH2 were also identiﬁed
and validated as putative miR-135b targets.
Materials and Methods
Mice
Female BALB/c and rat ErbB2 transgenic BALB-neuT
mice28 were bred by Biogem IRGS (Ariano Irpino, Italy),
maintained in the transgenic unit of the Molecular Biotech-
nology Center (University of Torino, Torino, Italy) under
a 12-hour light-dark cycle, and provided food and water ad
libitum. Mice were treated in conformity with European laws
and policies,29 and this study was approved by the Ethical
Committee of the University of Torino.
Cell Lines and Mammosphere Culture
BALB-neuT line 1 (TUBO cells),30 BALB-neuT line 2, and
BALB-neuT line 3 are derived from autochthonous ErbB2þ
mammary carcinomas arising in BALB-neuT female mice.
They were cultured in Dulbecco’s modiﬁed Eagle’s medium
with Glutamax 1 (Life Technologies, Monza, Italy), sup-
plemented with 20% heat-inactivated fetal bovine serum
(Invitrogen, Carlsbad, CA) (complete medium). TSA (a
highly aggressive and metastatizing cell line established from
a moderately differentiated mammary adenocarcinoma that
arose spontaneously in a BALB/c mouse)31 and 4T1 (mouse
breast cancer cells sourced from ATCC, Manassas, VA) cell
lines were maintained in RPMI 1640 medium (Life Tech-
nologies), supplemented with 10% heat-inactivated fetal
bovine serum (Invitrogen). TUBO, TSA, and 4T1 cells were
grown in adherent conditions as an epithelial monolayer in
mammosphere medium (serum-free Dulbecco’s modiﬁed
Eagle’s mediumeF12 medium supplemented with 20 ng/mL
basic ﬁbroblast growth factor, 20 ng/mL epidermal growthThe American Journal of Pathology - ajp.amjpathol.orgfactor, 5 mg/mL insulin, and 0.4% bovine serum albumin; all
from Sigma-Aldrich, Milano, Italy) to generate E cells.
TUBO cells were dissociated enzymatically and mechan-
ically, using trypsin and pipetting, andwere plated in ultralow
attachment ﬂasks (Corning Life Sciences, Amsterdam, The
Netherlands) at 6  104 viable cells/mL in mammosphere
medium, as previously described.32 Nonadherent spherical
clusters of cells, named P1, were collected by gentle centri-
fugation after 7 days and disaggregated through enzymatic
and mechanical dissociation. The cells were analyzed
microscopically for single cellularity and seeded again at 6
104 viable cells/mL to generate nonadherent spherical clusters
of cells, named P2.
RNA Isolation and RT-qPCR for mRNA and miRNA
Detection
Total RNAwas isolated from cells, mammospheres, and the II,
III, and IV right mammary glands of mice bearing diffused
atypical hyperplasia (6 weeks of age) and invasive lobular
carcinomas (19 weeks of age) using the mirVanamiRNA
isolation kit (Applied Biosystems, Milano, Italy). RNA was
estimated qualitatively with an Agilent 2100 Bioanalyzer
(Agilent Technologies, Cernusco sul Naviglio, Italy) and
quantiﬁed with a NanoVuePlus Spectrophotometer (GE
Healthcare, Milano, Italy). Total RNA was stored at 80C
until used. Quantitative PCRs (qPCRs) for miRNA detection
were performed with TaqMan MicroRNA Assays (Applied
Biosystems) on 10 ng total RNA, following manufacturer’s
instructions. FormRNAdetection, 1mg ofDNase-treatedRNA
(DNA-free kit; Ambion, Austin, TX)was retrotranscribedwith
RETROscript reagents (Ambion), and qPCRs were performed
using gene-speciﬁc primers (QuantiTect Primer Assay; Qia-
gen, Milano, Italy), SYBR Green (Applied Biosystems), and
the 7900HT RT-PCR System (Applied Biosystems). Quanti-
tative normalization was performed on the expression of
sno-412, U6, or b-actin for miRNA or mRNA detection,
respectively. The relative expression levels between samples
were calculated using the comparative DCT method.
35
EXIQON miRNA Expression Analysis
Two prototypic conditions were investigated using miRCUR-
YTM LNAArray, version 9.2 (EXIQON, San Francisco, CA),
miRNA expression arrays: 19-week-old BALB-neuT animals
(wk19.neu, three animals) and 10-week-old BALB-neuT
animals (wk10.neu, four animals). Microarray data were
generated by the EXIQON Proﬁling Service. The microarray
experiment was based on a reference design, in which the
reference is made of a pool of all samples under analysis.
Background correction was done using the convolution model
described by Ritchie et al33 using an offset value of one. Intra-
array Cy3/Cy5 normalization was done using the lowess
method. Differentially expressed miRNAs were detected by
regularized t-test using the oneChannelGUI Bioconductor
package34 (Supplemental Table S1).2059
Arigoni et alqPCR Low-Density miRNA Arrays
Four conditions were investigated using Applied Biosystems
Megaplex low-density qPCR miRNA expression arrays:
19-week-old BALB-neuT and BALB/c (wk19.neu and
wk19.BALB/c, respectively) and 6-week-old BALB-neuT
and BALB/c (wk6.neu and wk6.BALB/c, respectively) mice.
Two animals were analyzed for each condition. qPCR runs
were performed by technical support of Applied Biosystems.
Raw CT data were analyzed using Bioconductor.
36 Of 381
probes, 259 were left after removal of noninformative probes
(those with a CT >35 in six of eight samples). DCT values
were calculated with respect to the mammalian U6 endoge-
nous control (Supplemental Table S2). By using the rank
product method,37 differential expression was calculated
between wk19.neu and wk19.BALB/c, between wk6.neu
and wk6.BALB/c, and between wk19.neu and wk.6.neu.
This method addresses the multiple comparison problem
and performs P value correction by false-discovery rate,
comparing the true rank product distribution with a random
one deﬁned permuting miRNA labels in each of the cards
under analysis. Herein, we have used 1000 permutations and
a threshold of percentage of false-positive predictions of 0.05.
Massively Parallel Sequencing for miRNAs
Mammary glands from two wk19.BALB/c and two
wk19.neu were evaluated. Total RNA (1.5 mg) was used for
SOLiD short RNA library preparation, following manufac-
turer’s instructions (Applied Biosystems). Library prepara-
tion and sequence data generation were provided as service
by Genomnia Srl (Milano, Italy). SOLiD, version 3, sequence
data in color space, 35 color calls, were cleaned38 and trim-
med at 25 color calls to remove the P2 linker. Read mapping
was done on the subset of ENSEMBL noncoding RNA
(miRNA, rRNA, tRNA, small nucleolar RNA, and snRNA)
using SHRIMP software version 1.3.2 (Toronto, ON,
Canada)39 with the following parameters: -n 1, -w 170%, -M
miRNA, and -o 1. SHRIMP outputs were reformatted and
imported into oneChannelGUI.34 Differential expression
analysis on count data was done using negative binomial
dispersion40 implemented in the edger Bioconductor package
(threshold P  0.05) (Supplemental Table S3).
miR-135b Meta-Analysis of Human Breast Cancers
The associations between miR-135a and miR-135b expres-
sion and survival and/or distant metastasis relapse were
assessed using two data sets12,21 encompassing both miRNA
and mRNA expression. For both of these data sets available
on Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo; accession numbers GSE19536 and GSE22220), the
expression data of miR-135a and miR-135b were extracted
together with survival information. K-mean clustering (kZ 2)
was used to cluster samples in two groups: a set of samples
characterized by the highest miR-135a andmiR-135b average2060expression level (high) and a set of samples characterized by
the lowest miR-135a and miR-135b average expression level
(low). A Cox proportional hazards regression model was
ﬁtted to survival data for high and low groups in the two data
sets.
An Enerly et al12 data set was also used to search for anti-
correlation between miR-135b and its targets, MID1 and
MTCH2. Samples were stratiﬁed on the basis of subgroups,
as deﬁned by Perou et al.41 Linear regression was used to
measure and quantify anti-correlation between miR-135b
and MID1 and MTCH2 expression data using Spearman’s
rank correlation test. Values between 0 and 1 indicate the
presence of anti-correlation, whereas values between 0 and
1 indicate the presence of correlation.
Transient Cell Transfection
To obtain adherent TUBO or P1 derived cells silenced or
overexpressing miR-135b, 3 105 or 1.2 105 cells per well
in 6-well plates, respectively, were transfected using Lip-
ofectamine 2000 (Invitrogen) with 200 nmol/L of miR-135b
miRIDIAN Hairpin Inhibitor (antiemiR-135b antagomir) or
100 nmol/L of miR-135b miRIDIAN Mimics (miR-135b
mimic) (Dharmacon; Thermo Fisher Scientiﬁc, Waltham,
MA). For each experiment, cells were also transfected with
miRIDIAN microRNA Hairpin Inhibitor (scrambled anta-
gomir) or Mimics (scrambled mimic) negative controls. Cells
were tested for miR-135b knockdown or overexpression 24,
48, and 72 hours after transfection.
To demonstrate a causal role of MID1 and MTCH2
downstream of miR-135b, a rescue experiment was per-
formed by transfecting TUBO cells using Lipofectamine
2000 (Invitrogen) with 10 mg of plasmids containing the
cDNA of MID1 or MTCH2 genes without 30 untranslated
region (UTR; Gene-Copoeia, Rockville, MD) and, thus,
miR-135b insensitive. pVAX empty plasmid was used as
a control. Forty-eight hours later, TUBO cells were trans-
fected with 100 nmol/L of miR-135b miRIDIAN Mimics.
Twenty-four hours later, 5  104 TUBO cells from each
experimental condition were assayed in triplicate for their
ability to grow in an anchorage-independent condition. At
the same time, RNA was isolated from transfected cells to
test miR-135b, MTCH2, and MID1 expression.
To obtain the phenocopy of miR-135b overexpression,
knockdown of the MID1 target gene was obtained by trans-
fecting 3  105 TUBO cells with 200 nmol/L of speciﬁc
siRNA or nontargeting siRNA as control (ON-TARGET plus
SMART pool siRNA; Dharmacon).
Flow Cytometry Analysis
TUBO, P1, P2, and P1 cells 24 hours after transfection were
collected, disaggregated using enzymatic and mechanical
dissociation, and washed in PBS supplemented with 0.2%
bovine serum albumin and 0.01% sodium azide (Sigma-
Aldrich). Cell suspensions were either stained for membraneajp.amjpathol.org - The American Journal of Pathology
miR-135b and ErbB2þ Mammary Carcinomaantigens or ﬁxed and permeabilized with the Cytoﬁx/
Cytoperm Fixation/Permeabilization Kit (BD Biosciences,
Milano, Italy) and then stained for intracellular antigens.
The following antibodies were used: Alexa Fluor
647econjugated anti-stem cell antigen (Sca)-1, allophyco-
cyanin/Alexa Fluor 780econjugated anti-Thy1.1 from
Biolegend (London, UK), and Alexa Fluor 647econjugated
anti-Nanog monoclonal antibody from eBioscience (Hat-
ﬁeld, UK). Samples were collected and analyzed using
a CyAn ADP Flow Cytometer and Summit software version
4.3 (DakoCytomation, Heverlee, Belgium).
Sphere Generation Assay
TUBO cells were cultured at a density of 6  104 cells/mL
in a 6-well, ultralow attachment plate in the mammosphere
medium. After 5 days of culture, P1-derived cells were
transfected with antiemiR-135b antagomir or scrambled
antagomir. Five days after transfection, the total number of
mammospheres for each well was counted and reported as
number of mammospheres generated for every 103 cells
plated.
Anchorage-Independent Growth Assays
Twenty-four hours after transfection, 5  104 TUBO cells
were suspended in complete medium containing 0.45%Difco
Noble Agar (BD Biosciences) and plated in 6-cm bacterial
dishes. Mediumwas changed every 3 days. Fifteen days later,
the dishes were stained with nitroblue tetrazolium (Sigma-
Aldrich) and imaged with a Nikon SMZ1000 stereomicro-
scope. Colonies were counted with ImageJ software version
1.46 (NIH, Bethesda, MD).
Total Cell Count Assay
Twenty-four hours after transfection, TUBO cells were
plated at 5  103 cells per well in 96-well plates in Dul-
becco’s modiﬁed Eagle’s medium and starved for 24 hours.
Complete medium was then added, and cells were allowed
to grow for 1 to 4 days, ﬁxed with 2.5% glutaraldehyde, and
stained with 0.1% crystal violet. The dye was solubilized
using 10% acetic acid. Optical density was measured with
a Microplate Reader 680 XR (BioRad, Hercules, CA) at
a 570-nm wavelength.
In Vivo Tumor Growth and Metastasization
Seven-week-old BALB/c female mice were challenged in the
mammary pad with 1  105 TUBO cells. This pad was
inspected weekly by palpation. Progressively growing
masses >1 mm in diameter were regarded as tumors. Mice
were sacriﬁced when one tumor exceeded a 10-mm mean
diameter. For experimental metastasis assays, 2.5  104
TUBO, 5  104 TSA, or 4T1 cells were injected into the tail
vein of 7-week-old female BALB/c mice. Mice wereThe American Journal of Pathology - ajp.amjpathol.orgsacriﬁced 20 days later, and total lungs were formalin ﬁxed,
cut into small pieces, parafﬁn embedded, divided into
sections, and H&E stained. Micrometastases were evaluated,
using an Olympus (Milano, Italy) BH2 microscope on three
or more sections by using ImageJ software version 1.46.
miR-135b Target Identiﬁcation
Detection of miR-135b targets was done by downloading
from the Miranda database (http://www.microrna.org, last
accessed September 1, 2010)42 all those characterized by an
optimal or suboptimal miRSVR score,42 and retaining only
those with a human orthologue (The Jackson Laboratory, Bar
Harbor, ME; Mouse Genome Informatics Data and Statistical
Reports, Mammalian Orthology: ftp://ftp.informatics.jax.org/
pub/reports/index.html#orthology, last accessed September 1,
2010). The expression of these genes was then evaluated by
transcriptome analysis (MOUSEREF-8 V2 Illumina bead
chips, GSE28949, Illumina, San Diego, CA) in antiemiR-
135b or scrambled transfected TUBO cells at 24, 48, and 72
hours after transfection. Each experimental condition was
repeated three times. Complementary RNA synthesis and
labeling were done with the Illumina RNA Ampliﬁcation Kit
(Ambion), following manufacturer’s suggestions. Arrays were
scanned on an Illumina BeadStation 500. Genome studio
(Illumina) was used to generate a raw intensity signal without
normalization. Data log2 transformation and loess normaliza-
tion were performed with oneChannelGUI.34 After removal of
unchanged and not expressed genes by interquartile range
ﬁltering43 (only genes with an interquartile range >0.25 were
retained), and linear model analysis44 of differential expres-
sion, genes characterized by an uncorrected P < 0.05 and up-
regulated in antiemiR-135b, compared with scrambled
transfected TUBO cells, were considered for further analysis.
Luciferase Assay
A total of 3  105 TUBO cells were plated on a 6-well plate
and, 24 hours later, cotransfected using Lipofectamine 2000
(Invitrogen) with 200 nmol/L of antiemiR-135b or 100
nmol/L of miR-135b mimic with 1 mg of pEZX-MT01
vector (Gene-Copoeia) containing the ﬁreﬂy luciferase
gene, the 30 UTR of the indicated miR-135b potential target
genes, and renilla luciferase as the tracking gene. Lysates
were collected 72 and 96 hours after transfection, and ﬁreﬂy
and renilla luciferase activities were measured with a dual
Luciferase Reporter System (Promega, Madison, WI).
Protein Preparation and Immunoblotting
Total protein extracts were obtained from transfected TUBO
cells by using a boiling buffer containing 0.125 mol/L Tris/
HCl, pH 6.8, and 2.5% SDS. A protein-level evaluation of
MID1 and MTCH2 was performed on total lysates collect-
ed 72 or 48 hours after transfection, respectively. Proteins
(30 mg) were separated by SDS-PAGE and electroblotted2061
Figure 1 Principal component analysis of global miRNA expression
changes. Transcription proﬁling of mammary gland samples from 6-week-old
BALB-neuT (wk6.neu), 19-week old BALB-neuT (wk19.neu), and age-
matched wild-type BALB/c (wk6.BALB/c and wk19.BALB/c) mice was per-
formed using Applied Biosystems real-time PCR low-density miRNA arrays.
miRNA expression proﬁle changes are mainly linked to animal age; however,
that of invasive carcinoma is different from that of age-matched normal
mammary tissue (black closed versus white open circles), whereas that of
atypical hyperplasia and normal tissue is more similar (gray closed versus
white open circles). Amount of variance explained by each of the principal
component analysis components is shown in the inset.
Arigoni et alonto polyvinylidene ﬂuoride membranes (BioRad, Milano,
Italy). Membranes were blocked in 5% Blotto nonfat
milk (Santa Cruz Biotechnology, Santa Cruz, CA) and
Tris-buffered salineeTween buffer [137 mmol/L NaCl,
20mmol/LTris/HCl (pH7.6), and 0.1%Tween-20] for 1 hour
at 37C, then incubated with appropriate primary and
secondary antibodies in 1%milk Tris-buffered salineeTween
buffer, overnight at 4C and for 1 hour at room temperature,
respectively, and visualized by enhanced chemiluminescence
(Amersham Biosciences, Piscataway, NJ). The anti-MTCH2
rabbit polyclonal antibody was from ProteinTech (Chicago,
IL); the anti-MID1 rabbit polyclonal antibody was from
LSBio (Seattle, WA); and anti-actin mouse monoclonal, goat
anti-mouse IgG horseradish peroxidaseeconjugated, and
goat anti-rabbit IgG horseradish peroxidaseeconjugated
antibodies were all from Santa Cruz Biotechnology. Protein
modulations were calculated relative to controls, normalized
on the actin loading control, and expressed as percentages by
using Quantity One software version 4.6.3 (BioRad).
Results
Differential miRNA Expression in Invasive Carcinoma
and in Normal Tissue during ErbB2 Mammary
Carcinogenesis
To assess a correlation between deregulation of miRNAs and
breast cancer, miRNAproﬁlingwas performed inBALB-neuT
mice.24,28 Previous observations45 showed that changes in the
composition of mRNA species associated with modiﬁcation
of the cell composition of the mammary microenvironment
can be used to tag tumor/microenvironment-associated genes.
Herein, we used this approach to identify tumor-associated
miRNAs. Two prototypic conditions of autochthonous carci-
nogenesis were investigated: diffused atypical hyperplasia
present in themammary glands of wk6.neu and invasive lobular
carcinomas displayed by mammary glands of wk19.neu. Wild-
type mammary glands from age-matched BALB/c animals
(wk6.BALB/c andwk19.BALB/c) were included to account for
miRNA changes as the result of physiological changes of the
mammary glands. Transcription proﬁling was performed using
real-time PCR low-densitymiRNAarrays. Principal component
analysis shows that miRNA proﬁle changes are mainly linked
to animal age (Figure 1). However, some differences were
observed between atypical hyperplasia and invasive carcinoma
when they were compared with age-matched normal mammary
tissue (Figure 1). Rank product statistics37 did not disclose
signiﬁcant differences in miRNA expression of hyperplasia
versus age-matched normal mammary tissue (wk6.neu versus
wk6.BALB/c). In contrast, two tumor-associated miRNAs
(mmuemiR-135a and mmuemiR-135b) were differentially
expressed between lobular carcinoma and age-matched nor-
mal mammary tissue (wk19.neu versus wk19.BALB/c). Their
expression was conﬁrmed in the mammary glands of 19-week-
old BALB/c and BALB-neuT mice by qPCR on independent
samples. No differences in the expression level were observed2062comparing wk6.BALB/c with wk6.neu for both miR-135a
and miR-135b, whereas a statistically signiﬁcant increase
was observed comparing wk19.BALB/c with wk19.neu
(Figure 2). Furthermore, although miR-135a and miR-135b
expression levels were comparable between wk6.BALB/c and
wk19.BALB/c, a statistically signiﬁcant expression increment
was found comparing wk6.neu with wk19.neu (Figure 2, A and
B), suggesting a correlation between miRNA expression and
tumor mass increase.Massively parallel sequencing of RNA, or
RNA-seq, quantitative analysis performed on independent
samples displayed a statistically signiﬁcant increment only for
miR-135a and miR-135b in wk19.neu compared with that
measured in wk19.BALB/c (miR-135a log2 fold change, 3.19
false-discovery rate <0.05; miR-135b log2 fold change, 4.36
false-discovery rate <0.05). RNA-seq data were also used to
evaluate miR-135a and miR-135b absolute concentrations.
Their ranking in wk19.BALB/c and in wk19.neu showed that
they move from the bulk of low-expressed miRNAs (>200
miRNAs) to a subgroup with medium expression (approxi-
mately 60 miRNAs) (Supplemental Figure S1).miR-135a and miR-135b in Human Cancers
Little is known about the association of miR-135a and miR-
135bwith human breast cancer.13,14However, Blenkiron et al10
data set performed on 93 primary human breast tumors high-
lighted that miR-135b is up-regulated in basal and normal-like
breast cancer subgroups.41 Moreover, Enerly et al12 data setajp.amjpathol.org - The American Journal of Pathology
Figure 2 miR-135a (A) and miR-135b (B) expression levels measured in
the mammary glands of 6- and 19-week-old BALB/c (white open circles) and
BALB-neuT (black closed circles) mice measured by qPCR. Each dot repre-
sents the evaluation of miRNA levels in a single mouse. DCT values were
calculated with respect to the mammalian sno-412 RNA level. Statistically
signiﬁcant differences were calculated using the Student’s t-test: wk6.BALB/
c versus wk19.BALB/c (*PZ 0.01) for miR-135a, wk.6neu versus wk19.neu
(***P < 0.0001) for miR-135a and miR-135b, and wk19.BALB/c versus
wk19.neu (**P < 0.001 for miR-135b and ***P < 0.0001 for miR-135a).
Figure 3 miR-135b expression does not signiﬁcantly affect tumor cell
growth both in vitro and in vivo. TUBO cells were transfected with a speciﬁc
miR-135b antisense inhibitor (antiemiR-135b) or mimic (miR-135b-over)
or their negative controls (scrambled). A and B: TUBO cell proliferation was
evaluated 24, 48, 72, and 96 hours after down-regulation (A) or over-
expression (B) of miR-135b. Three independent experiments (at least in
quadruplicate) were performed, and a representative one is shown as means
 SEM. C and D: The miR-135b effect on TUBO cell growth in vivo was
evaluated after injecting s.c. into BALB/c mice antiemiR-135b
(C; continuous black line, n Z 11) or miR-135b-over (D; continuous black
line, n Z 7). In each experiment, TUBO cells were also transfected with
negative scrambled anti-miR (C; dotted black line, n Z 11) and a scram-
bled mimic (D; dotted black line, n Z 5). Data are expressed as tumor
incidence; differences were analyzed by the log-rank (Mantel-Cox) test.
miR-135b and ErbB2þ Mammary Carcinomaon 101 primary human breast tumors conﬁrmed the over-
expression ofmiR-135b in basal-like tumor subtypes. Genome-
wide investigations of miRNA status in primary human breast
cancers done by Enerly12 and Buffa21 and coworkers are
valuable tools to investigate the association between miRNA
expression and patient survival or distant metastasis relapse,
respectively. By using these data and applying a Cox propor-
tional hazards regression model, a statistical association
between miR-135b up-modulation and poor survival (P Z
0.04) was observed (Supplemental Figure S2A); however, no
correlation with late (ie, 120 months) distant metastasis was
revealed (Supplemental Figure S2B). Nevertheless, up-
modulation of miR-135b seems to be involved in early (ie, 50
months) distant metastasis relapse (Supplemental Figure S2C).
miR-135a expression does not show any signiﬁcant association
with patient survival and distantmetastasis appearance (data not
shown).
miR-135b Does Not Affect in Vitro or in Vivo
BALB-neuT Tumor Cell Line Proliferation
The overexpression of miR-135b in invasive mammary
tumors of BALB-neuT mice, together with its correlation
with poor survival in patients with breast cancer, prompted
us to explore its role in tumor cell proliferation. qPCR
performed on three cell lines derived from BALB-neuT
mammary tumors and on two other unrelated BALB/c
mammary tumor cell lines (TSA31 and 4T1) showed that
miR-135b was expressed in all tested cell lines, even if at
a lower level in both TSA and 4T1 cells compared with
BALB-neuT tumor cells (Supplemental Figure S3). The
consequences of miR-135b deregulation were investigated
in BALB-neuT line 1 (TUBO), TSA, and 4T1 cells. qPCR
analysis 72 hours after transfection showed that miR-135b
expression was almost completely abrogated when TUBO,
TSA, and 4T1 cells were transfected with speciﬁc antisenseThe American Journal of Pathology - ajp.amjpathol.orginhibitors (antiemiR-135b) and strongly up-regulated after
its transient overexpression by speciﬁc mimics (miR-135b-
over) (data not shown). By contrast, miR-135b expression
was not affected after transfection with negative controls
(scrambled). Both down-regulation and overexpression of
miR-135b had a marginal effect on TUBO total cell count
(Figure 3): only a 10% to 15% reduction of total cell number
was observed in antiemiR-135b compared with scrambled
TUBO cells (Figure 3A) and 5% to 20% enhancement of
total cell number in miR-135b-over compared with scram-
bled TUBO cells (Figure 3B). Comparable results were
observed when miR-135b deregulation was studied on both
TSA and 4T1 cells (data not shown). When TUBO cells in
which miR-135b was silenced or overexpressed were
injected s.c. in the ﬂank of BALB/c mice, only a marginal
effect on tumor incidence was observed (Figure 3, C and D),
although tumor growth speed was not affected at all (data
not shown).miR-135b Is Involved in CSC Self-Renewal
Because miRNAs are involved in CSC phenotype mainte-
nance by connecting stemness and metastasis,8 an in vitro
cultivation system that allows propagation of mammary
epithelial TUBO cells in suspension as nonadherent mam-
mospheres32 was used to assess the miR-135b level of
expression in TUBO cellederived nonadherent mammo-
spheres and in differentiated mammary TUBO cells.2063
Figure 4 miR-135b expression is signiﬁcantly higher in mammospheres compared with differentiated epithelial TUBO cells and is involved in CSC self-
renewal. A: Fluorescence-activated cell sorter (FACS) analysis of Sca-1, Thy1.1, and Nanog stem cell markers on TUBO, P1, and P2 mammospheres. Data
are expressed as means  SEM of the percentage of positive cells. A two-tailed Student’s t-test was used for comparisons between P1 or P2 mammospheres and
TUBO cells. *P Z 0.02, **P Z 0.002, and ***PZ 0.0009. B: miR-135b level in P1 and P2, measured by qPCR and expressed as 2DDC normalized to TUBO
cells grown in mammosphere medium. A two-tailed Student’s t-test was used for comparisons. yPZ 0.003. C: Sphere generation assay 5 days after transfection
of P1-derived cells with antiemiR-135b or scrambled antagomir. Data are expressed as mammosphere number per 103 plated cells. A two-tailed Student’s t-test
was used for comparisons. zP Z 0.01. D: FACS analysis of Sca-1, Thy1.1, and Nanog stem cell markers on P1-derived cells 24 hours after transfection with
antiemiR-135b or scrambled antagomir. Data are expressed as means  SEM of the percentage of positive cells. A two-tailed Student’s t-test was used for
comparisons between scrambled and miR-135b antagomir-transfected P1-derived cells. xP Z 0.004.
Arigoni et alFluorescence-activated cell sorter analysis of some stem cell
markers showed that the percentage of Sca-1,32 Thy1.1,46
and Nanog47 positive cells signiﬁcantly increased progres-
sively from TUBO to P1 and P2 passages of mammospheres
(Figure 4A). The level of miR-135b was signiﬁcantly higher
in P1 and P2 mammospheres compared with that of
differentiated TUBO cells (Figure 4B). Similar results were
observed when miR-135b expression was assessed in
mammospheres from TSA (Supplemental Figure S4). To
further analyze miR-135b involvement in CSC self-renewal,
P1 mammospheres were transfected with antiemiR-135b or
scrambled antagomir, and sphere generation was evaluated.
As reported in Figure 4C, miR-135b silencing signiﬁcantly
reduced mammosphere generation in a sphere generation
assay. This inhibition was associated with a reduction in the
percentage of Sca-1e, Thy1.1-, and Nanog-expressing cells
(Figure 4D).
miR-135b Overexpression Enhances Colony Formation
in Vitro and Metastasis Formation in Vivo
Enerly12 and Buffa21 and coworkers’ meta-analyses suggest
a correlation between miR-135b overexpression in breast2064cancer and poor survival and early metastasis relapse. We,
thus, looked to see whether miR-135b has any activity linked
to metastasis formation in BALB-neuT mammary cancer
cells. Anchorage-independent growth in soft agar was eval-
uated by both silencing and overexpressing miR-135b in
TUBO cells. AntiemiR-135b TUBO cells cultured in soft
agar showed a signiﬁcant reduction in the number of colonies
compared with those observed with scrambled TUBO cells
(98.3  14.4 versus 203.0  9.5 colonies; P Z 0.004)
(Figure 5A), whereas a signiﬁcant enhancement of the
number of colonies was observed in miR-135b-over
compared with scrambled TUBO cells (148.7  12.1
versus 96.5 10.4 colonies; PZ 0.02) (Figure 5B). Because
of its ability to enhance anchorage-independent growth, we
also investigated whether miR-135b inﬂuences metastasis
formation in vivo. Thus, antiemiR-135b or miR-135b-over
TUBO cells were injected into the tail vein of BALB/c mice,
and lung micrometastases were counted. AntiemiR-135b
TUBOcellswere signiﬁcantly (PZ 0.02) less able to seed and
formed fewer lungmetastases than the scrambled TUBO cells
(Figure 5C). In contrast, signiﬁcantly (PZ 0.01) more lung
metastases were observed for miR-135b-over when compared
with scrambled TUBO cells (Figure 5D). Up-regulation ofajp.amjpathol.org - The American Journal of Pathology
Figure 5 miR-135b expression signiﬁcantly enhances anchorage-
independent growth in vitro and metastasis formation in vivo. TUBO cells were
transfected with speciﬁc antiemiR-135b (A and C: black bars) or miR-135b
mimic (B and D: black bars) or their scrambled controls (white bars). A and B:
TUBO cell ability to grow in soft agar and form colonies was evaluated 15 days
after down-regulation (A) or overexpression (B) of miR-135b. Three indepen-
dent experiments were performed in triplicate, and a representative one is
shown. Results are shown as means  SEM of one of three independent
experiments. A two-tailed Student’s t-test was used for comparisons. *P Z
0.02; **PZ 0.004. C andD: Lungmicrometastasis formation was evaluated 20
days after tail vein injection of transfected TUBO cells in BALB/cmice (nZ 4 to
5mice for each group) on H&E-stained total lung sections. Results are shown as
means SEM of one out of three independent experiments performed in trip-
licates. A two-tailed Student's t-test was used for comparisons. *PZ 0.02.
miR-135b and ErbB2þ Mammary CarcinomamiR-135b in both TSA and 4T1 cells resulted in an increase of
the number of lung metastases when injected in BALB/c
mice, suggesting a role of miR-135b in tumor metastatization
in these tumor cell lines (Supplemental Figure S5).
miR-135b Target Genes
The ﬁrst step in the detection of miR-135b targets was the
extraction of all predicted mouse miR-135b targets (3888
genes) from theMiranda database (http://www.microrna.org,
last accessed September 1, 2012),42 retaining only those
having a human orthologue (1054 genes). The following step
was to evaluate their differential expression in antiemiR-
135b or in scrambled TUBO cells 72 hours after transfection
by Illumina microarrays. More important, qPCR data showed
that miR-135b expression reached nearly 100% of reduction
only at 72 hours (Supplemental Figure S6). The 17 genes up-
regulated in antiemiR-135b TUBO cells were considered as
putative miR-135b targets (Table 1). Because down-
regulation of two of them only (MID1 and MTCH2) was
known to be associated with a more aggressive phenotype in
solid tumors,48,49 we focused our attention on them.
To determine whether MID1 and MTCH2 are bona ﬁde
targets of miR-135b, two reporter vectors with MID1 and
MTCH2 30 UTR fragments containing the miR-135b binding
sequences (Supplemental Figure S7) were used to perform
luciferase assays. As shown in Figure 6A, luciferase expres-
sion driven by the 30 UTRs of MID1 and MTCH2 was signif-
icantly enhanced in antiemiR-135b compared with scrambled
TUBO cells. Consistent with the luciferase and the genome-
wide microarray analysis results, MID1 and MTCH2 mRNA
levels, measured by qPCR, were signiﬁcantly enhanced in
antiemiR-135bTUBOcells comparedwith those in scrambled
TUBO cells (Figure 6B). Modulation of MID1 and MTCH2
mRNAs corresponded to ﬂuctuations of MID1 and MTCH2
protein levels (10% and 20%, respectively) in antiemiR-135b
compared with those measured in scrambled TUBO cells
(Figure 6C). Moreover, miR-135b overexpression in TUBO
cells was associated with a decrease of MID1 and MTCH2
protein levels (93% and 23%, respectively) (Figure 6C).
We then investigated the possible direct regulation of MID1
and MTCH2 by miR-135b in vivo, by comparing their mRNA
expression during BALB-neuT mammary tumor progression.
A signiﬁcant reduction in mRNA of MID1 and MTCH2 was
observed in wk19.neu versus wk6.neu mammary glands
(Figure 6D).
To evaluate whether the prometastatic effect mediated by
miR-135b is MID1 or MTCH2 dependent, we measured the
anchorage-independent colony formation ability of miR-135b
overexpressing TUBO cells also expressing MID1 or
MTCH2 coding sequences lacking the 30 UTR; therefore, they
yielded a product resistant to miR-135bemediated suppres-
sion. miR-135b mimicetransfected TUBO cells over-
expressing MID1 or MTCH2 miR-135beinsensitive cDNA
showed a signiﬁcant reduction of colony formation ability
compared with that measured in miR-135b mimic TUBOThe American Journal of Pathology - ajp.amjpathol.orgcells also transfected with the empty plasmid (Figure 7). In
addition, to further conﬁrm the direct link between MID1
and colony formation ability of TUBO cells, a phenocopy
experiment of miR-135b overexpression was performed
by silencing the MID1 target gene with speciﬁc siRNA.
Signiﬁcantly more colonies were observed after MID1
knockdown (Supplemental Figure S8). Taken together, these
data indicate that the down-regulation of MID1 and MTCH2
by miR-135b is the mechanism by which miR-135b promotes
anchorage-independent progression of ErbB2-driven mam-
mary carcinomas.2065
Table 1 miR-135b Putative Targets
Probe ID Entrez ID Gene symbol Log2 FC variation
Log2 average
ﬂuorescence intensity P value
ILMN_1238032 242960 FBXL5 0.73 9.87 0.001
ILMN_1244768 20818 SRPRB 1.12 10.35 0.002
ILMN_2619452 17318 MID1 0.54 8.38 0.003
ILMN_2718612 68291 MTO1 0.56 9.37 0.004
ILMN_2654568 72133 TRUB1 0.71 9.13 0.007
ILMN_2914271 11836 ARAF 0.82 11.32 0.010
ILMN_2755981 226151 FAM178A 0.97 10.11 0.011
ILMN_2610204 56428 MTCH2 0.64 9.52 0.011
ILMN_2710705 18412 SQSTM1 0.89 12.36 0.015
ILMN_2668387 106143 CGGBP1 0.59 11.39 0.020
ILMN_2737296 102436 LARS2 0.41 9.28 0.022
ILMN_1229418 12807 HPS3 0.56 8.99 0.022
ILMN_1226187 14768 LANCL1 0.72 9.82 0.023
ILMN_3009880 242700 IL28RA 0.36 8.78 0.024
ILMN_1258977 67878 TMEM33 0.78 11.28 0.039
ILMN_1225723 72085 OSGEPL1 0.45 9.36 0.042
ILMN_2757150 18555 PCTK1 0.50 10.01 0.047
The 17 genes in the table were obtained by the intersection of genes detected as up-regulated on miR-135b silencing (P  0.05) and the putative target of
miR-135b extracted from the Miranda database.
FC, fold change.
Arigoni et alTaking advantage of the available data on miRNA status
and mRNA transcription proﬁle, published by Enerly et al,12
we looked for the presence of an anti-correlation between
miR-135b expression and MID1 or MTCH2 modulation
in primary human breast cancers. Because miR-135b is
signiﬁcantly up-modulated only in basal and normal-like
breast cancer subtypes, as shown by Blenkiron et al,10 we
stratiﬁed the mRNA data on the basis of the clinical anno-
tation available for the Enerly et al12 data set. A clear anti-
correlation between miR-135b and MID1 and MTCH2 was
found in the subset of tumors deﬁned as normal-like
(Supplemental Figure S9), reinforcing the relevance of
miR-135b and its targets in breast tumorigenesis.
Discussion
During the past 10 years, miRNAs have attracted attention
because of their ability to post-transcriptionally modulate the
expression of oncogenes and oncosuppressors. Several
reports have described their involvement in the initiation and
progression of most cancers. miRNAs overexpressed in
tumors contribute to oncogenesis by deregulating tumor
suppressors, whereas miRNAs lost by tumors participate in
oncogene overexpression. Notably, roles of miRNAs in
cancer are tissue and tumor speciﬁc, and alterations in
miRNA expression alone can cause cell neoplastic trans-
formation.50 In addition, a specialized family of miRNAs
(metastamir) modulates the metastatic behavior of neoplastic
cells51 and is involved in the regulation of the epithelial-
mesenchymal transition.52 miRNAs may also contribute to
the metastatic program by both modulating the structure of
local tumor microenvironment and promoting neoangio-
genesis during tumor progression.532066The mutated form of the rat ErbB2 oncogene drives
aggressive mammary carcinogenesis in BALB-neuT mice.
The steps of this progression, mimicking a few features of
human breast tumors,23 have been extensively characterized
at the transcriptional level.54e56 The analysis of miRNA
expression reported herein shows increased expression of
miR-135a and miR-135b during tumor expansion in func-
tion of the mouse age. The decreased expression of these
two miRNAs observed in function of the age in the
mammary glands of normal mice endorses their involve-
ment in tumor development.
Little is known about the expression of these two miR-
NAs in tumors. miR-135a down-regulation has been asso-
ciated with the anti-cancer effect of mistletoe lectin-I57 and
with a higher probability of relapse in patients with classic
Hodgkin lymphoma.58 Recently, miR-135a and miR-135b
up-modulation has been shown to correlate with the de-
gree of malignancy in colon cancer,59e61 osteosarcoma,62
ependymoma,63 and hepatocellular carcinoma.64 Although
miR-135a and miR-135b involvement in breast cancer has
never been described, by exploiting data on the expression
of miRNAs in human breast cancers,12,21 the overexpression
of miR-135b, but not miR-135a, appeared to be associated
with poor prognosis. In addition, miR-135b overexpression
in basal-like and estrogen-negative human tumors, shown
by this meta-analysis, ﬁts in well with the notion that
mammary tumors of BALB-neuT mice are similar to basal-
like and estrogen-negative human mammary carcinomas.26
TUBOcellswere established fromaBALB-neuTmammary
carcinoma.65 As expected, because TUBO cells are ErbB2
addicted, miR-135b expression was not strictly involved in
promoting their proliferation, neither in vitro nor in vivo, but
was associated with their anchorage-independent growth andajp.amjpathol.org - The American Journal of Pathology
Figure 6 miR-135b down-regulates MID1 and MTCH2 target genes. A:
Luciferase assays performed on TUBO cells cotransfetced with reporter
constructs containing the 30 UTR of the indicated genes cloned downstream
of the luciferase coding sequence, together with antiemiR-135b or
scrambled anti-miR. Results were calculated as fold changes and are shown
as means  SEM of ﬁreﬂy luciferase activity relative to controls, normalized
on renilla luciferase activity. A two-tailed Student’s t-test was used for
comparisons. *P Z 0.03. Three independent experiments were performed
in triplicate, and a representative one is shown. B: MID1 and MTCH2 mRNA
levels measured by qPCR in TUBO cells 72 hours after antiemiR-135b or
scrambled anti-miR transfection. Results were calculated as fold changes
(means  SEM) relative to scrambled, normalized on b-actin. A two-tailed
Student’s t-test was used for comparisons. *P Z 0.03, **P Z 0.001. C:
MID1 and MTCH2 protein levels measured by using Western blot analysis in
TUBO cells transfected with antiemiR-135b (left panels), miR-135b mimic
(right panels), or their scrambled controls. The percentage indicated on
the right refers to protein modulations. D: MID1 and MTCH2 mRNA levels
measured by qPCR in the mammary tissue from 6-week-old (wk6.neu, white
bars) and 19-week-old (wk19.neu, black bars) BALB-neuT mice. Results
were calculated as fold changes (means  SEM) relative to wk6.neu,
normalized on b-actin. For all data, a two-tailed Student’s t-test was used
for comparisons. *P Z 0.02, ***P Z 0.0002.
Figure 7 miR-135b prometastatic effect is mediated by MID1 and
MTCH2. Number of soft agar colonies generated from TUBO cells transfected
with miR-135beinsensitive MID1 (MID1 ins), MTCH2 (MTCH2 ins), or the
empty vector (as control) and then with miR-135b mimic. Three indepen-
dent experiments were performed in triplicate, and a representative one is
shown. A two-tailed Student’s t-test was used to compare each experi-
mental condition with that of miR-135beoverexpressing TUBO cells
transfected also with empty plasmid. *P Z 0.04.
miR-135b and ErbB2þ Mammary Carcinomatheir ability to produce lung metastasis. Moreover, expression
of miR-135b increases in nonadherent spherical clusters of
different breast cancer cell lines that display increased tu-
morigenic and metastatic ability.32 Furthermore, miR-135b
involvement in CSC phenotype maintenance is demonstrated
by the signiﬁcant reduction of mammospheres after its
silencing in P1-derived TUBO cells.
To investigate the molecular mechanism underlying miR-
135b functionality, we searched for its targets by computa-
tional prediction. However, the speciﬁcity and sensitivity of
the existing algorithms are still too poor to generate mean-
ingful, workable hypotheses for subsequent experimental
testing.66 Integration of prediction with other experimental
methods investigating target modulation is, thus, required to
improve target detection speciﬁcity. Although miRNAs onlyThe American Journal of Pathology - ajp.amjpathol.orgpartially suppress gene expression and promote mRNA
decay, a certain effect at the level of target mRNA concen-
tration can be detected with carefully designed microarray
experiments.67 Combining target prediction knowledge
derived from Miranda with a gene expression proﬁle exper-
iment, in which we look for up-regulated genes after miR-
135b silencing in TUBO cells, we detected 17 putative
targets. However, among all these genes, only MID1 and
MTCH2 expression was associated with a statistically
signiﬁcant up-regulation 72 hours after miR-135b silencing
in TUBO cells, suggesting a direct link to this miRNA.
Moreover, MID1 and MTCH2 down-modulation in tumor
cells has been reported to be associated with a more
aggressive phenotype, which is part of a gene signature
associated with metastasis and survival in solid tumors.48,49
MID1 forms homodimers that associate with microtubules
in the cytoplasm, and is probably involved in the formation of
multiprotein structures acting as anchor points for microtu-
bules.68 MTCH2, also called Met-induced mitochondrial
protein,69 is an outer mitochondrial membrane protein whose
induction causes growth and motility arrest in vitro and loss
of tumorigenicity in vivo69 and facilitates apoptosis.70 The
luciferase assay showed that both are bona ﬁde miR-135b
targets. The role of miR-135b in anchorage-independent
cell growth and the fact that MID1 and MTCH2 down-
regulation is associated with increased invasiveness in both
BALB-neuT mice and in solid human cancers48,49 indicate
a role of miR-135b in invasion and metastasis formation in
breast cancer. Moreover, the presence of an anti-correlation
between miR-135b and MID1 and MTCH2 expressions in
human breast cancer specimens of normal-like subtype2067
Arigoni et alhighlighted the relevance of the whole study for the under-
standing of human breast cancer.
The detection of the role of miR-135b in BALB-neuT
mammary carcinogenesis provides a well-characterized pre-
clinical model for exploration of the potentiality of miR-
135b, MID1, and MTCH2 as new therapeutic targets.
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